Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize Sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABOS	$2.51	+1.62%	487.04K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABOS	$2.51	+1.6%	487.04K
3
4
5
6

ABOS

Get Acumen Pharmaceuticals, Inc. Data in Excel

Get Acumen Pharmaceuticals, Inc. Data in Excel